ALTERTOX

🚧𝗪𝗲𝗯𝘀𝗶𝘁𝗲 𝗨𝗻𝗱𝗲𝗿 𝗥𝗲𝗰𝗼𝗻𝘀𝘁𝗿𝘂𝗰𝘁𝗶𝗼𝗻🚧  Dear Visitors, "We are currently working on an exciting update and rebranding to enhance your Altertox experience.  We apologize for any inconvenience this may cause and appreciate your patience as we work to improve our services.  Please check back soon for the launch of our new and improved website. In the meantime, feel free to contact us at [email protected] for any inquiries about communication, policy, consulting, training or TATAbox.    Thank you for your understanding!" The Altertox Team 

🌟 𝗛𝗼𝘄 𝗡𝗔𝗠𝘀 𝗔𝗿𝗲 𝗦𝗵𝗮𝗽𝗶𝗻𝗴 𝘁𝗵𝗲 𝗙𝘂𝘁𝘂𝗿𝗲 𝗼𝗳 𝗧𝗼𝘅𝗶𝗰𝗼𝗹𝗼𝗴𝘆? 🌟 Over the past few weeks, we have explored the transformative potential of New Approach Methodologies (#NAMs) in our ALTERTOX 𝗡𝗔𝗠𝘀 𝗞𝗻𝗼𝘄𝗹𝗲𝗱𝗴𝗲-𝗦𝗵𝗮𝗿𝗶𝗻𝗴 𝗖𝗮𝗺𝗽𝗮𝗶𝗴𝗻. From revolutionizing research practices to advancing animal welfare, NAMs are paving the way for innovative, human-relevant testing alternatives. 🧪🔬 🎥 Today, we conclude this series with insightful reflections from our Policy Officer, Leonie Mueller, on the future of NAMs in toxicology. She addresses to key questions:  🔹 𝗛𝗼𝘄 𝗱𝗼 𝘆𝗼𝘂 𝗲𝗻𝘃𝗶𝘀𝗶𝗼𝗻 𝘁𝗵𝗲 𝗿𝗼𝗹𝗲 𝗼𝗳 𝗡𝗔𝗠𝘀 𝗲𝘃𝗼𝗹𝘃𝗶𝗻𝗴 𝗶𝗻 𝘁𝗼𝘅𝗶𝗰𝗼𝗹𝗼𝗴𝘆? 🔹 𝗪𝗵𝗮𝘁 𝗮𝗱𝘃𝗶𝗰𝗲 𝘄𝗼𝘂𝗹𝗱 𝘆𝗼𝘂 𝗼𝗳𝗳𝗲𝗿 𝘁𝗼 𝗿𝗲𝘀𝗲𝗮𝗿𝗰𝗵𝗲𝗿𝘀 𝗮𝗻𝗱 𝗽𝗼𝗹𝗶𝗰𝘆𝗺𝗮𝗸𝗲𝗿𝘀 𝗻𝗮𝘃𝗶𝗴𝗮𝘁𝗶𝗻𝗴 𝘁𝗵𝗲 𝗰𝗼𝗺𝗽𝗹𝗲𝘅𝗶𝘁𝗶𝗲𝘀 𝗼𝗳 𝗡𝗔𝗠𝘀 𝗶𝗺𝗽𝗹𝗲𝗺𝗲𝗻𝘁𝗮𝘁𝗶𝗼𝗻 𝗮𝗻𝗱 𝘃𝗮𝗹𝗶𝗱𝗮𝘁𝗶𝗼𝗻? Catch Leonie's take in the video. 🙏 𝗧𝗵𝗮𝗻𝗸 𝗬𝗼𝘂 to everyone who has followed and engaged with this series!  Let’s continue the conversation on NAMs! 🚀 #NAMs #ScienceCommunication #3Rs #AlternativesToAnimalTesting #Altertox 

We're excited to share our latest newsletter, as we wrap up the year.   This month's highlights include: 🔹 𝗘𝘂𝗿𝗼𝗽𝗲𝗮𝗻 𝗣𝗮𝗿𝗹𝗶𝗮𝗺𝗲𝗻𝘁 𝗜𝗻𝘁𝗲𝗿𝗴𝗿𝗼𝘂𝗽𝘀 (2024-2029) – A look at new cross-party working groups focusing on health, rare diseases, and animal welfare. Notably, there's a growing need for a dedicated intergroup on Artificial Intelligence. 🔹 𝗘𝗨 𝗔𝗴𝗲𝗻𝗰𝗶𝗲𝘀 𝗖𝗼𝗹𝗹𝗮𝗯𝗼𝗿𝗮𝘁𝗶𝗼𝗻 – A summary of the recent ENVI Committee session with European Medicines Agency (#EMA) , European Environment Agency (#EEA), European Food Safety Authority (EFSA), European Chemicals Agency (#ECHA), and European Centre for Disease Prevention and Control (ECDC) directors discussing their work and commitment to public health, safety, and chemical regulations. 🔹 𝗜𝗻 𝗩𝗶𝘁𝗿𝗼 𝗧𝗼𝘅𝗶𝗰𝗼𝗹𝗼𝗴𝘆 & 𝗜𝗡𝗩𝗜𝗧𝗘𝗦-𝗜𝗡 𝗙𝗿𝗮𝗺𝗲𝘄𝗼𝗿𝗸 – A new item bank to enhance the 𝗶𝗻𝘁𝗲𝗿𝗻𝗮𝗹 𝘃𝗮𝗹𝗶𝗱𝗶𝘁𝘆 𝗼𝗳 𝘪𝘯 𝘷𝘪𝘵𝘳𝘰 𝘁𝗼𝘅𝗶𝗰𝗼𝗹𝗼𝗴𝘆 𝘀𝘁𝘂𝗱𝗶𝗲𝘀, crucial for advancing New Approach Methodologies (NAMs). 🔹 𝗘𝘅𝗽𝗼𝘀𝗼𝗺𝗲 𝗠𝗼𝗼𝗻𝘀𝗵𝗼𝘁 𝗙𝗼𝗿𝘂𝗺 – An upcoming event focused on global coordination for studying the human exposome and advancing environmental health research. 🔹 𝗡𝗔𝗠𝗪𝗜𝗦𝗘 𝗣𝗿𝗼𝗷𝗲𝗰𝘁 – The European initiative coordinated by @INERIS to advance the adoption of NAMs for assessing the safety and efficacy of chemicals and pharmaceuticals. ALTERTOX leading communication and dissemination efforts. 🔹 PrecisionTox 𝗖𝗮𝗳é 𝗦𝗰𝗶𝗲𝗻𝘁𝗶𝗳𝗶𝗾𝘂𝗲 – Session in 𝗝𝗮𝗻𝘂𝗮𝗿𝘆 2025 on advancing NAMs in regulatory toxicology, featuring experts from #ECHA, University of Birmingham, and ALTERTOX. 🔹 𝗟𝗼𝗼𝗸𝗶𝗻𝗴 𝗕𝗮𝗰𝗸 𝗮𝘁 2024 – Highlights from our team and events throughout 2024.  𝗥𝗲𝗮𝗱 𝘁𝗵𝗲 𝗳𝘂𝗹𝗹 𝗻𝗲𝘄𝘀𝗹𝗲𝘁𝘁𝗲𝗿 𝗵𝗲𝗿𝗲 👉https://lnkd.in/dQWn969p We extend our heartfelt thanks to you for your continued support and collaboration.  Wishing you a joyous holiday season and a prosperous New Year! 🎄✨ #PolicyNews #Toxicology #NAMs #EUPolicy #AI #Exposome #Altertox 

🌟𝗔𝘂𝗱𝗶𝗼𝘃𝗶𝘀𝘂𝗮𝗹 𝗣𝗿𝗼𝗱𝘂𝗰𝘁𝗶𝗼𝗻 𝗦𝘁𝘂𝗱𝗲𝗻𝘁 𝗝𝗼𝗯 𝗮𝘁 ALTERTOX🌟  We have had the pleasure of working with Adriana Cubells Lalanne as our Audiovisual Production Assistant and we're excited to share a bit about her journey during her student job with us. If you’re looking to apply your audiovisual production skills in a supportive and collaborative environment, through a student job or internship, reach out to us at [email protected]. We’d love to hear from you!

𝗬𝗲𝘀𝘁𝗲𝗿𝗱𝗮𝘆 𝘄𝗮𝘀𝗻’𝘁 𝗷𝘂𝘀𝘁 𝗮 𝘁𝗲𝗮𝗺-𝗯𝘂𝗶𝗹𝗱𝗶𝗻𝗴 𝗲𝘃𝗲𝗻𝘁—𝗶𝘁 𝘄𝗮𝘀 𝗮 𝗱𝗮𝘆 𝗼𝗳 𝗽𝗼𝘀𝘀𝗶𝗯𝗶𝗹𝗶𝘁𝗶𝗲𝘀! ✨  We kicked things off with energizing activities that had us laughing, learning and stepping out of our comfort zones 💪. We engaged in interactive games that challenged our strategy and teamwork 🧠🤝, followed by dynamic brainstorming sessions that sparked creativity 💡 and allowed us to share insights to propel us forward 🚀. Most importantly, these moments strengthened the bonds that make our team truly unstoppable. 💛 A huge thank you to everyone in our team for bringing creativity, curiosity, and enthusiasm to the table. 🙌 Your engagement and ideas are what make experiences like these so impactful! 🌟 #TeamBuilding #Altertox 

Over the past few weeks, we’ve explored 𝗡𝗲𝘄 𝗔𝗽𝗽𝗿𝗼𝗮𝗰𝗵 𝗠𝗲𝘁𝗵𝗼𝗱𝗼𝗹𝗼𝗴𝗶𝗲𝘀 (#𝗡𝗔𝗠𝘀) as part of our ALTERTOX 𝗡𝗔𝗠𝘀 𝗞𝗻𝗼𝘄𝗹𝗲𝗱𝗴𝗲-𝗦𝗵𝗮𝗿𝗶𝗻𝗴 𝗖𝗮𝗺𝗽𝗮𝗶𝗴𝗻—looking at how they’re transforming research, advancing animal welfare, and providing innovative alternatives to traditional testing. This campaign was brought to life by the contributions of this incredible team: 🖊️ 𝗪𝗿𝗶𝘁𝗲𝗿: Monicah Kirathi – Translating complex science into relatable, digestible content.  🎨 𝗚𝗿𝗮𝗽𝗵𝗶𝗰 𝗗𝗲𝘀𝗶𝗴𝗻𝗲𝗿: Aurélia Boige – Designing visuals that connect with the story we’re telling.  🔎 𝗥𝗲𝘃𝗶𝗲𝘄𝗲𝗿: Leonie Mueller – Ensuring scientific accuracy and clarity. 💬 "𝙒𝙚’𝙫𝙚 𝙚𝙣𝙟𝙤𝙮𝙚𝙙 𝙚𝙭𝙥𝙡𝙤𝙧𝙞𝙣𝙜 𝙉𝘼𝙈𝙨 𝙬𝙞𝙩𝙝 𝙮𝙤𝙪 𝙖𝙣𝙙 𝙝𝙖𝙫𝙚 𝙗𝙚𝙚𝙣 𝙞𝙣𝙨𝙥𝙞𝙧𝙚𝙙 𝙗𝙮 𝙩𝙝𝙚 𝙘𝙤𝙣𝙫𝙚𝙧𝙨𝙖𝙩𝙞𝙤𝙣𝙨 𝙨𝙥𝙖𝙧𝙠𝙚𝙙 𝙗𝙮 𝙩𝙝𝙞𝙨 𝙘𝙖𝙢𝙥𝙖𝙞𝙜𝙣. 𝙏𝙝𝙖𝙣𝙠 𝙮𝙤𝙪 𝙛𝙤𝙧 𝙚𝙣𝙜𝙖𝙜𝙞𝙣𝙜, 𝙨𝙝𝙖𝙧𝙞𝙣𝙜 𝙮𝙤𝙪𝙧 𝙞𝙣𝙨𝙞𝙜𝙝𝙩𝙨 𝙖𝙣𝙙 𝙟𝙤𝙞𝙣𝙞𝙣𝙜 𝙩𝙝𝙚 𝙙𝙞𝙖𝙡𝙤𝙜𝙪𝙚!" We’re wrapping up this series with our 𝗳𝗶𝗻𝗮𝗹 𝗤&𝗔 𝗽𝗼𝘀𝘁 𝗻𝗲𝘅𝘁 𝗪𝗲𝗱𝗻𝗲𝘀𝗱𝗮𝘆! ❓ 𝗚𝗼𝘁 𝗾𝘂𝗲𝘀𝘁𝗶𝗼𝗻𝘀 𝘆𝗼𝘂’𝗱 𝗹𝗶𝗸𝗲 𝘁𝗼 𝘀𝗲𝗲 𝗮𝗱𝗱𝗿𝗲𝘀𝘀𝗲𝗱? Drop them in the comments below. 👇 #NAMs #ScienceCommunication #3Rs #TeamSpotlight #AlternativesToAnimalTesting #Altertox 

 ✨ 𝗥𝗲𝗰𝗮𝗽 𝗳𝗿𝗼𝗺 𝘁𝗵𝗲 PEPPER 𝗦𝗬𝗠𝗣𝗢𝗦𝗜𝗨𝗠 ✨ Last week, we joined the Pepper Anniversary Congress which brought 𝗽𝘂𝗯𝗹𝗶𝗰 𝗮𝘂𝘁𝗵𝗼𝗿𝗶𝘁𝗶𝗲𝘀, 𝗽𝗼𝗹𝗶𝗰𝘆𝗺𝗮𝗸𝗲𝗿𝘀, 𝗮𝗻𝗱 𝗿𝗶𝘀𝗸 𝗮𝘀𝘀𝗲𝘀𝘀𝗺𝗲𝗻𝘁 𝗲𝘅𝗽𝗲𝗿𝘁𝘀 from key institutions such as: French Ministries  European Commission DG ENV  Joint Research Center (DG JRC)  Bundesinstitut für Risikobewertung (German Federal Institute for Risk Assessment)  The Dutch Ministry  European Chemicals Agency (ECHA)   The discussions focused on much more than the achievements of the 𝗣𝗲𝗽𝗽𝗲𝗿 𝗣𝗹𝗮𝘁𝗳𝗼𝗿𝗺 itself. The real emphasis was on the why and how of validation: 👉 𝗪𝗵𝘆 𝗱𝗼 𝘄𝗲 𝗻𝗲𝗲𝗱 𝗳𝗮𝘀𝘁𝗲𝗿 𝗮𝗻𝗱 𝗺𝗼𝗿𝗲 𝗲𝗳𝗳𝗲𝗰𝘁𝗶𝘃𝗲 𝘃𝗮𝗹𝗶𝗱𝗮𝘁𝗶𝗼𝗻 𝗺𝗲𝘁𝗵𝗼𝗱𝘀?  👉 𝗛𝗼𝘄 𝗰𝗮𝗻 𝘄𝗲 𝗮𝗰𝗰𝗲𝗹𝗲𝗿𝗮𝘁𝗲 𝘁𝗵𝗲 𝗽𝗿𝗼𝗰𝗲𝘀𝘀 𝘁𝗵𝗿𝗼𝘂𝗴𝗵 𝗶𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝗼𝗻 𝗮𝗻𝗱 𝘀𝘁𝗿𝗮𝘁𝗲𝗴𝗶𝗰 𝗽𝗮𝗿𝘁𝗻𝗲𝗿𝘀𝗵𝗶𝗽𝘀?  👉 𝗪𝗵𝗮𝘁 𝗿𝗼𝗹𝗲 𝗱𝗼𝗲𝘀 𝗰𝗿𝗼𝘀𝘀-𝘀𝗲𝗰𝘁𝗼𝗿 𝗰𝗼𝗹𝗹𝗮𝗯𝗼𝗿𝗮𝘁𝗶𝗼𝗻 𝗽𝗹𝗮𝘆 𝗶𝗻 𝗮𝗱𝗱𝗿𝗲𝘀𝘀𝗶𝗻𝗴 𝘁𝗵𝗲𝘀𝗲 𝗰𝗵𝗮𝗹𝗹𝗲𝗻𝗴𝗲𝘀? A key takeaway?  Validation efforts must evolve through pragmatic, policy-driven approaches and strengthened partnerships. There’s immense potential in public-private partnerships, improved governance models, strategic prioritization, and aligning validation efforts of endocrine disruptors with policy needs. We’re excited to build on the shared insights. ---- #PepperSymposium #EndocrineDisruptors #InnovationInScience #PublicHealth #ScientificCollaboration #Validation #EUHealth #HealthProtection  ---- Ofelia Bercaru / Cécile Lemaître / Bob Diderich  / Maurice Whelan / Philippe Hubert  / Pascal Sanders  / Matthew Burbank  / Gregory Lemkine  / Joëlle Rüegg  

We’re on site at the PEPPER 𝗦𝗬𝗠𝗣𝗢𝗦𝗜𝗨𝗠: “𝙀𝙣𝙙𝙤𝙘𝙧𝙞𝙣𝙚 𝘿𝙞𝙨𝙧𝙪𝙥𝙩𝙤𝙧𝙨: 𝘼𝙘𝙘𝙚𝙡𝙚𝙧𝙖𝙩𝙞𝙣𝙜 𝙈𝙚𝙩𝙝𝙤𝙙𝙨 𝙑𝙖𝙡𝙞𝙙𝙖𝙩𝙞𝙤𝙣 𝙩𝙤 𝙄𝙢𝙥𝙧𝙤𝙫𝙚 𝙊𝙪𝙧 𝙋𝙧𝙤𝙩𝙚𝙘𝙩𝙞𝙤𝙣, 5 𝙔𝙚𝙖𝙧𝙨 𝙤𝙛 𝘼𝙘𝙝𝙞𝙚𝙫𝙚𝙢𝙚𝙣𝙩𝙨 𝙖𝙣𝙙 𝙋𝙚𝙧𝙨𝙥𝙚𝙘𝙩𝙞𝙫𝙚𝙨 𝙤𝙛 𝙩𝙝𝙚 𝙋𝙚𝙥𝙥𝙚𝙧 𝙋𝙡𝙖𝙩𝙛𝙤𝙧𝙢.”  We’re happy to be part of this important event, where 𝗼𝘃𝗲𝗿 20 𝗲𝘀𝘁𝗲𝗲𝗺𝗲𝗱 𝘀𝗽𝗲𝗮𝗸𝗲𝗿𝘀—including policymakers, risk assessment agencies, and experts from both public and private laboratories—are leading open and pragmatic discussions that are shaping the future of our understanding and protection against 𝗲𝗻𝗱𝗼𝗰𝗿𝗶𝗻𝗲 𝗱𝗶𝘀𝗿𝘂𝗽𝘁𝗼𝗿𝘀. A huge thank you to the organisers, speakers, participants, and partners for making this symposium a powerful catalyst for change. 𝗞𝗲𝗲𝗽 𝗽𝗼𝘀𝘁𝗲𝗱 𝘁𝗼 𝗴𝗲𝘁 𝘁𝗵𝗲 𝗶𝗻𝘀𝗶𝗴𝗵𝘁𝘀 𝗮𝗻𝗱 𝘁𝗮𝗸𝗲-𝗵𝗼𝗺𝗲 𝗺𝗲𝘀𝘀𝗮𝗴𝗲𝘀 𝗶𝗻 𝗮 𝗳𝗼𝗹𝗹𝗼𝘄𝗶𝗻𝗴 𝗽𝗼𝘀𝘁. #PepperSymposium #EndocrineDisruptors #InnovationInScience #PublicHealth #ScientificCollaboration #EventCommunication #DigitalCommunication #DigitalStrategy #HealthProtection

🚨𝗘𝗣𝗔𝗔 3𝗥𝘀 𝗦𝘁𝘂𝗱𝗲𝗻𝘁 𝗚𝗿𝗮𝗻𝘁𝘀 2025: 𝗖𝗮𝗹𝗹 𝗳𝗼𝗿 𝗦𝘂𝗯𝗺𝗶𝘀𝘀𝗶𝗼𝗻𝘀 🚨  The 2025 EPAA European Partnership for Alternative Approaches 3𝗥𝘀 𝗦𝘁𝘂𝗱𝗲𝗻𝘁 𝗚𝗿𝗮𝗻𝘁𝘀 are now 𝗼𝗽𝗲𝗻 𝗳𝗼𝗿 𝗮𝗽𝗽𝗹𝗶𝗰𝗮𝘁𝗶𝗼𝗻𝘀! These grants support students and young scientists working on 𝗮𝗹𝘁𝗲𝗿𝗻𝗮𝘁𝗶𝘃𝗲 𝗮𝗽𝗽𝗿𝗼𝗮𝗰𝗵𝗲𝘀 𝘁𝗼 𝗮𝗻𝗶𝗺𝗮𝗹 𝘁𝗲𝘀𝘁𝗶𝗻𝗴 to attend a high-profile scientific event dedicated to the #3Rs (Replacement, Reduction, Refinement).  💡 𝗪𝗵𝗮𝘁’𝘀 𝗼𝗻 𝗼𝗳𝗳𝗲𝗿?   The EPAA is offering 2 𝗳𝘂𝗹𝗹 𝗴𝗿𝗮𝗻𝘁𝘀 𝗼𝗳 €1,000 each to participate in the following events.   💠 MPS World Summit 2025 (Brussels, Belgium, June 9-13) - Application deadline 14/02/2025 💠 Society of Environmental Toxicology and Chemistry (SETAC) 2025 (Vienna, Austria, May 11-15) - Application deadline 14/02/2025 💠 EUROTOX Congress 2025 (Athens, Greece, September 14-17) - Application deadline 15/05/2025  These grants cover event 𝗿𝗲𝗴𝗶𝘀𝘁𝗿𝗮𝘁𝗶𝗼𝗻, 𝘁𝗿𝗮𝘃𝗲𝗹, and 𝗮𝗰𝗰𝗼𝗺𝗺𝗼𝗱𝗮𝘁𝗶𝗼𝗻 expenses (based on receipts).  💡 𝗪𝗵𝗼 𝗰𝗮𝗻 𝗮𝗽𝗽𝗹𝘆?  💠 Applicants must be 𝗯𝗮𝘀𝗲𝗱 𝗶𝗻 𝗼𝗻𝗲 𝗼𝗳 𝘁𝗵𝗲 27 𝗘𝗨 𝗰𝗼𝘂𝗻𝘁𝗿𝗶𝗲𝘀 or the 𝗨𝗞 (citizenship can be from anywhere). 💠 Applicants must have 𝗴𝗿𝗮𝗱𝘂𝗮𝘁𝗲𝗱 𝘄𝗶𝘁𝗵 𝗮 𝗕𝗦𝗰 (or equivalent, with at least 180 ECTS credits) by the time of application, but 𝗰𝗮𝗻𝗻𝗼𝘁 𝗵𝗮𝘃𝗲 𝗮 𝗱𝗼𝗰𝘁𝗼𝗿𝗮𝗹 𝗱𝗲𝗴𝗿𝗲𝗲. 💠 Applicants must still be considered 𝗳𝘂𝗹𝗹-𝘁𝗶𝗺𝗲 𝘀𝘁𝘂𝗱𝗲𝗻𝘁𝘀 𝗼𝗿 𝘆𝗼𝘂𝗻𝗴 𝘀𝗰𝗶𝗲𝗻𝘁𝗶𝘀𝘁𝘀 (𝘂𝗻𝗱𝗲𝗿 35 𝘆𝗲𝗮𝗿𝘀 𝗼𝗹𝗱) at the time of application. 💠 Young scientists employed by industry are 𝗻𝗼𝘁 𝗲𝗹𝗶𝗴𝗶𝗯𝗹𝗲 to apply. 💠 No other funding or reimbursement for the same event from any other entity is allowed. 🔗 𝗛𝗼𝘄 𝘁𝗼 𝗮𝗽𝗽𝗹𝘆:   For full details on the eligibility criteria and submission guidelines, visit the website: https://lnkd.in/dnsyVUrA 

⭐ 𝗦𝘂𝗰𝗰𝗲𝘀𝘀 𝗦𝘁𝗼𝗿𝗶𝗲𝘀 𝗼𝗳 𝗡𝗔𝗠𝘀 𝗜𝗺𝗽𝗹𝗲𝗺𝗲𝗻𝘁𝗮𝘁𝗶𝗼𝗻 𝗶𝗻 𝗧𝗼𝘅𝗶𝗰𝗼𝗹𝗼𝗴𝘆 ⭐  The integration of #NAMs is revolutionizing drug development, offering predictive, efficient, and humane alternatives to traditional animal testing. These innovations are not only enhancing our ability to assess drug safety and efficacy but are also reducing costs and accelerating time-to-market. Here are three 𝗻𝗼𝘁𝗲𝘄𝗼𝗿𝘁𝗵𝘆 𝗲𝘅𝗮𝗺𝗽𝗹𝗲𝘀 of NAMs successfully implemented in clinical practice and drug development: 🔬𝗛𝘂𝗺𝗮𝗻-𝗦𝗶𝗺𝘂𝗹𝗮𝘁𝗶𝗻𝗴 𝗖𝗵𝗶𝗽 𝗶𝗻 𝗖𝗮𝗻𝗰𝗲𝗿 𝗗𝗿𝘂𝗴 𝗗𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁 Scientists at The Hebrew University of Jerusalem have made groundbreaking strides by using a human-simulating chip to develop a cancer drug, eliminating the need for animal testing. This chip mimics human organ functions, allowing researchers to test drug effects on the kidney, liver, and heart. By combining cisplatin (a cancer drug) with empagliflozin (a diabetes medication), they significantly reduced fat buildup in the liver. This breakthrough accelerates drug development and improves testing accuracy. The team is now advancing the drug combination toward clinical trials, patent submission, and FDA approval. 🚀 🧠3𝗗 𝗕𝗹𝗼𝗼𝗱-𝗕𝗿𝗮𝗶𝗻 𝗕𝗮𝗿𝗿𝗶𝗲𝗿 𝗠𝗼𝗱𝗲𝗹 𝗳𝗼𝗿 𝗚𝗹𝗶𝗼𝗯𝗹𝗮𝘀𝘁𝗼𝗺𝗮 𝗧𝗿𝗶𝗮𝗹𝘀 At Roche, researchers have successfully utilized a 3D blood-brain barrier- glioblastoma model to optimize the starting dose for a first-in-human (FIH) trial of T-cell bispecific constructs. This model offers a more accurate representation of human physiology, improving the safety and efficacy of clinical trials. The translational strategy was presented to the FDA and Danish Health Authority, receiving regulatory approval in Europe, the USA, Canada, and Australia. 🌍💡 💉𝗧𝗿𝗮𝗻𝘀𝗶𝘁𝗶𝗼𝗻 𝗳𝗿𝗼𝗺 𝗜𝗻 𝗩𝗶𝘃𝗼 𝘁𝗼 𝗜𝗻 𝗩𝗶𝘁𝗿𝗼 𝗣𝗼𝘁𝗲𝗻𝗰𝘆 𝗔𝘀𝘀𝗮𝘆𝘀 𝗳𝗼𝗿 𝗙𝗲𝗿𝘁𝗶𝗹𝗶𝘁𝘆 𝗛𝗼𝗿𝗺𝗼𝗻𝗲𝘀  For decades, fertility hormones such as Follicle Stimulating Hormone (FSH) have been evaluated using the Steelman-Pohley in vivo bioassay for market batch release. Merck has pioneered an in vitro potency assay as a viable alternative to this traditional approach. After extensive testing and validation, Merck demonstrated that the in vitro assay could effectively replace the in vivo bioassay, offering similar performance in assessing hormone activity and detecting molecular changes. This transition was supported by an in-depth structure-activity relationship (SAR) analysis. The new in vitro method has since been approved in numerous countries, with continued global adoption. This achievement underscores Merck's dedication to advancing the #3Rs principles —reducing animal testing, improving release timelines, and ensuring the highest standards in drug quality control. 💊 Do you know of any other successful NAMs implementations in toxicology? Share your stories and insights in the comments below! 👇